GOTHENBURG, Sweden, Feb. 5, 2025 /PRNewswire/ — Zinzino group revenue increased with a total of 57%, compared with the previous year.
The revenue in January for Zinzino’s sales markets increased by 62% and amounted to SEK 228.7 (140.9) million. Faun Pharma’s external sales decreased and amounted to SEK 4.7 (8.1) million. Overall, the Group increased revenues by 57% to SEK 233.4 (149.0) million compared with the previous year.
Revenues were distributed as follows:
Regions, mSEK |
25-Jan |
24-Jan |
Change |
The Nordics |
25.5 |
22.8 |
12% |
Central Europe |
69.5 |
40.9 |
70% |
East Europe |
34.2 |
31.8 |
8% |
South & West Europe |
44.6 |
22.0 |
101% |
The Baltics |
10.3 |
8.0 |
29% |
North America |
22.2 |
10.4 |
113% |
Asia-Pacific |
20.8 |
4.0 |
420% |
Africa |
1.6 |
1.0 |
60% |
Zinzino |
228.7 |
140.9 |
62% |
Faun Pharma |
4.7 |
8.1 |
-42% |
Zinzino Group |
233.4 |
149.0 |
57% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
–Central Europe: Austria, Germany, Switzerland
–East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
-The Baltics: Estonia, Latvia, Lithuania
–North America: Canada, USA, Mexico
–Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
–Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, www.zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
Certified Adviser: Carnegie Investment Bank AB (publ.)
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/zinzino/r/zinzino-ab–publ–preliminary-sales-report-january-2025,c4100794
The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/zinzino-ab-publ-preliminary-sales-report-january-2025-302368653.html
SOURCE Zinzino
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.